1. Is a good quality company?
Data is not available for this company.
2. Is undervalued or overvalued?
The key valuation ratios of Piramal Phytocare Ltd. - (Amalgamated)'s currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||-75.6%||-61.6%||-6.7%||-33.3%||-30.4%||-34.6%||-49.2%||3.8%||363%||52.2%||-|
|Value Creation Index ⓘ||NA||NA||-1.5||-3.4||-3.2||-3.5||-4.5||-0.7||NA||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||156.2%||-82%||83.9%||13.7%||-23.8%||39.2%||-34.7%||476.5%||5.5%||-|
|Adj EPS ⓘ||-50.9||-56.1||-2.8||-2.5||-1.6||-1.3||-1.3||0.1||-8.7||-3.2||-3.7|
|YoY Gr. Rt. %||-||NA||NA||NA||NA||NA||NA||NA||-12457.1%||NA||-|
|BVPS (₹) ⓘ||-58.4||-114.6||8.6||6.2||4.5||3.2||1.9||2||-6.7||-9.8||-12.1|
|Adj Net Profit ⓘ||-130||-143||-7.2||-6.4||-4.2||-3.5||-3.3||0.2||-22.5||-8.2||-10|
|Cash Flow from Ops. ⓘ||-118||-99.2||-1.7||-2.9||1.1||0.1||2.2||-0.5||-1||-13.7||-|
|Debt/CF from Ops. ⓘ||-2.8||-4.9||0||-0.1||0||0||0||0||0||-1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||NA||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||156.3||65.5||5.4||-33.7||-30.7||-34.6||-49.2||3.8||363.2||38.3||34.1|
|Op. Profit Mgn % ⓘ||-1631.8||-587.4||-99||-46||2.7||17.9||18||-1.3||-95||-29.8||-35.9|
|Net Profit Mgn % ⓘ||-2099.8||-903.3||-253.9||-123||-71.2||-76.4||-51.6||4.6||-94.3||-32.8||-42.2|
|Debt to Equity ⓘ||-2.2||-1.7||0||0||0||0||0||0||0||-0.5||-|
|Working Cap Days ⓘ||703||427||1,580||205||136||197||157||227||64||90||95|
|Cash Conv. Cycle ⓘ||67||80||237||105||77||117||99||104||7||-123||0|
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
|TTM EPS (₹)||-3.7||-|
|TTM Sales (₹ Cr.)||23||-|
|BVPS (₹.) ⓘ||-12.1||-|
|Reserves (₹ Cr.) ⓘ||-57||-|
|From the Market|
|52 Week Low / High (₹)||22.40 / 24.55|
|All Time Low / High (₹)||3.40 / 519.80|
|Market Cap (₹ Cr.)||58.5|
|Equity (₹ Cr.)||26|
|Face Value (₹)||10|
|Industry PE ⓘ||36.3|
Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.
PLSL is focused on four therapeutic areas - Cancer, Diabetes, Inflammation and Infectious Diseases. The company has a pipeline of fourteen compounds, including four in clinical trials. PLSL's lead chemical compound, a Cdk-4 inhibitor, has completed two Phase I studies and is being tested in another Phase I/II trial for Multiple Myeloma. PLSL has drug discovery and development agreements with Eli Lilly & Company and Merck & Company, two of the leading pharmaceutical companies in the world.
PLSL has been listed on the National Stock Exchange and the Bombay Stock Exchange since June 2008.
PLSL partners with leading Indian educational institutes to form a research collaborations namely Anna University, Chennai, Indian Institute of Science, Bangalore, Regional Research Laboratory, Jammu, Central Drug Research Institute, Lucknow, National Institute of Immunology, Delhi, National Institute of Oceanography, Goa, and Indian Institute of Chemical Biology, Kolkata.
The company has fourteen compounds in pipeline that includes four in clinical trials. PLSLâ€™s lead chemical compound a Cdk-4 inhibitor has successfully completed two phase studies and will be tested in another Phase I/II trials.
The company has a number of molecules in its research pipeline - in oncology (biological targets: Cyclin Dependent Kinase Cell Cycle inhibitors, Hypoxia Inducible Factor-1a (HIF-1a) Inhibitors, PI3 Kinase Inhibitors), inflammation (TNF - Production / Release Inhibitors, Safer NSAIDs), diabetes (Insulin Sensitizers [non-PPAR], GPR40 Modulators) and infectious disease (Microbial extracts: Antibacterial, Microbial extracts: Antifungal). PLSL also has a comprehensive library of plant extracts and microbial strains.
The companyâ€™s research vision and strategy is based on three core principles:Provide scientists state-of-the-art infrastructure to produce world-class science. Leverage Indiaâ€™s bio-diversity and wealth of knowledge on traditional systems of medicines to source drug lead molecules. And collaborate with academic institutions. Following are the research activities:
Awards & Achievements